Mathieu Blery PhD

Mathieu Blery is the Chief Scientific Officer and co-founder of KALSIOM SAS. KALSIOM is developing first-in-class therapies to treat rare auto-immune disorders with a high medical need. He is Experience in innovative first-in-class therapeutic antibodies development in immunology (lirilumab, monalizumab, advoralimab, IPH4102, IPH4301, LumoxitiTM), translational research, target discovery, and validation. He has 16 years of experience in the biopharmaceutical industry. Previous 7 years in academic research as a student and postdoctoral fellow in immunology.